JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spira, T. J.
Right arrow Articles by Pellett, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spira, T. J.
Right arrow Articles by Pellett, P. E.

Journal of Clinical Microbiology, June 2000, p. 2174-2180, Vol. 38, No. 6
0095-1137/00/$04.00+0

Comparison of Serologic Assays and PCR for Diagnosis of Human Herpesvirus 8 Infection

Thomas J. Spira,1,* Lee Lam,1 Sheila C. Dollard,2 Yuan-Xiang Meng,2 Chou Pong Pau,1 Jodi B. Black,2,dagger Darrell Burns,2 Brian Cooper,1 Melissa Hamid,2 Joe Huong,2 Kathleen Kite-Powell,2 and Philip E. Pellett2

Immunology Branch, Division of AIDS, STD, and TB Laboratory Research,1 and Viral Exanthems and Herpesvirus Branch, Division of Viral and Rickettsial Diseases,2 National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

Received 8 September 1999/Returned for modification 8 December 1999/Accepted 10 March 2000

A variety of assays for the diagnosis human herpesvirus 8 (HHV-8) infection have been reported. We compared several such assays with a panel of 88 specimens from human immunodeficiency virus (HIV)-infected patients with Kaposi's sarcoma (KS) (current-KS patients; n = 30), HIV-infected patients who later developed KS (later-KS patients; n = 13), HIV-infected patients without KS (no-KS patients; n = 25), and healthy blood donors (n = 20). PCR assays were also performed with purified peripheral blood mononuclear cells (PBMCs) to confirm positive serologic test results. The order of sensitivity of the serologic assays (most to least) in detecting HHV-8 infection in current-KS patients was the mouse monoclonal antibody-enhanced immunofluorescence assay (MIFA) for lytic antigen (97%), the orfK8.1 peptide enzyme immunoassay (EIA) (87%), the orf65 peptide EIA (87%), MIFA for latent antigen (83%), the Advanced Biotechnologies, Inc., EIA (80%), and the orf65 immunoblot assay (80%). Combination of the results of the two peptide EIAs (combined peptide EIAs) increased the sensitivity to 93%. For detection of infection in later-KS patients, the MIFA for lytic antigen (100%), the orfK8.1 peptide EIA (85%), and combined peptide EIAs (92%) were the most sensitive. Smaller percentages of no-KS patients were found to be positive (16 to 56%). Most positive specimens from the current-KS and later-KS groups were positive by multiple assays, while positive specimens from the no-KS group tended to be positive only by a single assay. PCR with PBMCs for portions of the HHV-8 orf65 and gB genes were positive for less than half of current-KS and later-KS patients and even fewer of the no-KS patients. The concordance between serologic assays was high. We propose screening by the combined peptide EIAs. For specimens that test weakly positive, we recommend that MIFA for lytic antigen be done. A positive result with a titer of >= 1:40 would be called HHV-8 positive. A negative or low titer would be called HHV-8 negative. If a population has a high percentage of persons who test positive by the combined peptide EIAs, then a MIFA could be performed with the negative specimens to determine if any positive specimens are being missed. Alternatively, if a population has a low percentage that test positive, then a MIFA could be performed with a subset of the negative specimens for the same reason. As described above, only a titer of >= 1:40 would be considered HHV-8 positive.

* Corresponding author. Mailing address: Centers for Disease Control and Prevention, 1600 Clifton Rd., A25, Atlanta, GA 30333. Phone: (404) 639-3938. Fax: (404) 639-2108. E-mail: tjs1{at}cdc.gov.

dagger Present address: National Institutes of Health, NCI/HAMB, Bethesda, Md.

Journal of Clinical Microbiology, June 2000, p. 2174-2180, Vol. 38, No. 6
0095-1137/00/$04.00+0


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2000 by the American Society for Microbiology. All rights reserved.